Pfizer’s Covid-19 vaccine immune response may be weaker in people older than 80, study shows

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
0:00
play article
Subscribers can listen to this article
Doctor makes vaccination to senior woman with surgical mask
Doctor makes vaccination to senior woman with surgical mask
Jasmin Merdan

The Covid-19 vaccines that have been approved for use have been carefully tested on tens of thousands of participants in clinical trials.

However, these studies have largely excluded people who are older and 80, for many reasons, including safeguarding their health. Still, people in this age group have a high risk of severe Covid-19 or death, or if they contract the SARS-CoV-2 virus.

To shed light on how well the two-dose Pfizer-BioNTech vaccine works in people who are older than 80 in the real world, a team of researchers from the University of Cambridge carried out a post-vaccination immunogenicity study in the elderly population and younger healthcare workers. Immunogenicity refers to how effectively a vaccine can provoke an immune response. 

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism. You can cancel any time.
Subscribe
Already a subscriber? Sign in
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
30% - 9645 votes
No
70% - 22651 votes
Vote